# A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab

> **NCT02515734** · PHASE2 · UNKNOWN · sponsor: **Japan Clinical Cancer Research Organization** · enrollment: 360 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** irinotecan
- **DRUG:** oxaliplatin
- **BIOLOGICAL:** bevacizumab
- **BIOLOGICAL:** cetuximab

## Key facts

- **NCT ID:** NCT02515734
- **Lead sponsor:** Japan Clinical Cancer Research Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2017-12
- **Final completion:** 2020-06
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2015-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02515734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02515734, "A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02515734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*